June 18, 2024 – Talk Bio

Caplyta Achieves Significant Victory in Major Depressive Disorder Trial, Paving Way for Competition with Vraylar

10 months ago talkbio0Tagged AbbVie, adjunctive therapy, Antipsychotic Agents, Approved, Caplyta, Clinical Trials, Depressive disorder, Intra-Cellular Therapies, Lumateperone, Major Depressive Disorder, United States Food and Drug Administration, Vraylar

Caplyta, lumateperone, Intra-Cellular Therapies, major depressive disorder, MDD, Vraylar, AbbVie, antipsychotic, adjunctive therapy, FDA approval, clinical trials

AstraZeneca’s Truqap Combo Fails to Improve Survival in Phase III Triple-Negative Breast Cancer Trial

10 months ago talkbio0Tagged AKT1 protein, human, AstraZeneca, CAPItello-290, capivasertib, Overall Survival, paclitaxel, Phase 3 Clinical Trials, PIK3CA gene, PTEN gene, Triple Negative Breast Neoplasms, Truqap

AstraZeneca, Truqap, capivasertib, Phase III trial, triple-negative breast cancer, CAPItello-290, paclitaxel, overall survival, PIK3CA, AKT1, PTEN

Aerovate Therapeutics’ Shares Plummet 93.3% After Disappointing IMPAHCT Study Results for AV-101 in Pulmonary Arterial Hypertension

10 months ago talkbio0Tagged 4-aminohippuric acid, Aerovate, AV-101, Biotech Stocks, Clinical Trials, Drug Formulation Process, imatinib, IMPAHCT, Inspiration function, Pulmonary arterial hypertension

Aerovate Therapeutics, AV-101, IMPAHCT Study, Pulmonary Arterial Hypertension, PAH, Imatinib, Inhaled Formulation, Biotech Stocks, Clinical Trials

Marea Therapeutics Secures $190M for Cardiometabolic Medicine Development

10 months ago talkbio0Tagged ANGPTL4 gene, cardiometabolic medicine, Cardiovascular Diseases, clinical-stage program, Marea Therapeutics, metabolic dysfunction, Monoclonal Antibodies, Phase 2 trial, Science of genetics

Marea Therapeutics, cardiometabolic medicine, clinical-stage program, genetics, ANGPTL4, monoclonal antibody, phase 2 trial, metabolic dysfunction, cardiovascular disease.